Search
for

    Did you mean JAK1/2 inhibitor?
    Glossary JAK1/2 inhibitor

    medication that blocks enzymes involved in immune signaling

    A JAK1/2 inhibitor is a type of medication that blocks the activity of Janus kinase 1 and 2 (JAK1 and JAK2), which are enzymes involved in the signaling pathways that regulate immune responses and inflammation. By inhibiting these enzymes, JAK1/2 inhibitors can help treat conditions like rheumatoid arthritis and certain types of alopecia, where the immune system mistakenly attacks the body's own tissues.

    Related Terms

    Sort by

    Research 30 of 778

    1. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015 · 184 citations
    2. JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician Journal of Family Medicine and Primary Care · 2024 · 6 citations
    3. Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus Annals of the rheumatic diseases · 2020 · 16 citations
    4. At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors JAAD case reports · 2020 · 4 citations
    5. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells International Journal of Molecular Sciences · 2020 · 16 citations
    6. Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy JAAD Case Reports · 2023 · 7 citations
    7. Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib The Nishinihon Journal of Dermatology · 2022 · 1 citations
    8. JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report 2024
    9. JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata 2023
    10. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream Pharmaceutics · 2021 · 24 citations
    11. Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review 2026
    12. Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata 2021 · 14 citations
    13. 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study Journal of The American Academy of Dermatology · 2021 · 1 citations
    14. Baricitinib Demonstrates Rapid Action Within Just 2 Months of Treatment in Severe and Unresponsive Alopecia Areata: A Case Report 2024
    15. Hair regrowth in a patient with central centrifugal cicatricial alopecia after a 2-month trial of baricitinib JAAD Case Reports · 2023 · 2 citations
    16. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition Nature medicine · 2014 · 701 citations
    17. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata JCI insight · 2016 · 196 citations
    18. Novel TMEM173 Mutation and the Role of Disease Modifying Alleles Frontiers in immunology · 2019 · 47 citations
    19. Baricitinib: From Rheumatoid Arthritis to COVID‐19 Journal of clinical pharmacology · 2021 · 42 citations
    20. Ruxolitinib for the treatment of severe alopecia areata Journal of the American Academy of Dermatology · 2018 · 37 citations
    21. STAT5 Activation in the Dermal Papilla Is Important for Hair Follicle Growth Phase Induction Journal of Investigative Dermatology · 2016 · 32 citations
    22. A novel therapeutic paradigm for patients with extensive alopecia areata Expert Opinion on Biological Therapy · 2016 · 30 citations
    23. Treatment of severe alopecia areata with baricitinib JAAD Case Reports · 2019 · 25 citations
    24. Application of Baricitinib in Dermatology Journal of inflammation research · 2022 · 14 citations
    25. Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib Frontiers in Immunology · 2021 · 6 citations
    26. Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study Clinical Cosmetic and Investigational Dermatology · 2024 · 4 citations
    27. Inhibition of T-cell activity in alopecia areata: recent developments and new directions Frontiers in immunology · 2023 · 4 citations
    28. Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata Rheumatology · 2022 · 3 citations
    29. A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata Journal of health economics and outcomes research · 2026
    30. Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED Journal of Human Immunity · 2026